Loading…

Xencor, Inc.XNCRCompetitor analysis, valuation and peers

United States · USD·Health Care›Biotechnology

Engineers antibody drugs using its Xtend and bispecific technology, licensed to pharma partners and developed internally.

Momentum leader 99
Mkt cap
$2.58B
US dollars, full cap
Free float
94%
of shares outstanding
$/day
$57.0M
20-day average traded
Fwd P/E
n/m
no positive forecast
ROIC−WACC
-45.3 pp
WACC 8.8%
Hurdle
n/a
no reverse DCF
Next earnings
98 days
24 Feb 2027
Close · USD$34.39
1D-0.3%
1W-14.0%
1M+37.9%
3M+27.4%
6M+203.8%
YTD+124.6%
1Y+120.2%
ATR %5.9%
Beta1.24
52w lowhigh15.3% off high

What Xencor does

Engineers antibody drugs using its Xtend and bispecific technology, licensed to pharma partners and developed internally.

Collects royalties on partners' approved drugs that use its Xtend technology, which keeps antibodies in the blood longer, such as Ultomiris from AstraZeneca's Alexion and Monjuvi from Incyte, plus milestone payments on others. It spends that cash on its own cancer and autoimmune antibody drugs.

Products and services

  • Xtend half-life extension technology (licensed)
  • Internal bispecific antibody pipeline (autoimmune, oncology)

Customers

  • Pharma partners including Alexion/AstraZeneca and

Where it sits in the supply chain

  • Health Care
  • Biotechnology
  • Antibody engineering platform

What could go right

  • Royalty revenue growth from partnered drugs
  • Internal pipeline clinical progress

What could go wrong

  • Dependence on partner drug commercial success
  • Clinical trial failure risk for internal pipeline

Moat: narrow (IP / patents, process know-how). Widely licensed Xtend antibody engineering technology embedded in multiple approved partner drugs generates royalties.

Headquarters: Pasadena, California, US · Founded: 1997 · Employees: 260

Named competitors

Xencor at a glance

Size Xencor (XNCR) is a United States Health Care company (Biotechnology) with a market value of $2.58B, the 1628th largest of 3,085 United States companies the cockpit tracks. Shares closed at $34.39 on 18 Nov 2026.

Performance Over six months the shares gained 203.8%, against -4.6% for the median peer and -2.2% for the United States market (cap-weighted) — highest of 21 in its peer set.

Growth Revenue grew 33.5% over the last twelve months (peer median +9.4%); the operating margin is -72.7% (peer median -2.6%).

Valuation It trades at 11.7× enterprise value to sales against a peer median of 7.7× (7th most expensive of 17).

Capital Return on invested capital runs 45.3 points below its cost of capital (8.8% WACC).

Short interest Short interest is 17.2% of the free float (30 Oct 2026).

Next results Next results expected around 24 Feb 2027 (exchange calendar; dates can move).

Relative performance

10020030021 May 202621 Aug 202618 Nov 2026XNCR 305Peer median 96
Six months, rebased to 100: Xencor against the median of its 20 peers (local-currency closes).

Xencor financials

Reported figures in USD; fiscal year ends 2025-12-31. TTM = trailing twelve months.
TTMFY2025FY2024FY2023FY2022
Revenue$200M$126M$110M$175M$165M
Revenue growth—+14%-37%+6%—
Gross profit$191M$115M$98.4M$163M$156M
EBITDA-$136M-$167M-$166M-$121M-$72.2M
Net income-$118M-$91.9M-$233M-$133M-$55.2M
Free cash flow-$176M-$138M-$208M-$96.4M-$14.0M
Capital expenditure$4.09M$3.15M$9.51M$21.3M$43.4M
Total debt$160M$188M$232M$252M$59.6M

Quarterly statements and history in the cockpit →

Xencor competitor charts

The default views of Competitor Analysis ▸ Charts, drawn from the same data. Open them in the cockpit to change the axes, pin companies and read every value.

Performance: 6-month against 1-month return

0%+100%+200%-20%0%+20%688278MBX30014202830068879688BAVA300255RCUSRUBICONLKFTDNLIVIMIAN302440TLXADMAXNCR6-month return →1-month return →
Up and to the right = strong over both horizons. Xencor is the large dot.

Fundamentals: revenue growth against valuation

0%+100%0×20×40×68827830014202830068879688BAVA3002552228RCUSRUBICONTLXBEAMXNCRRevenue growth (TTM) →EV / Sales →
Further right = faster growth; higher = more expensive. The dashed lines are the peer medians. Xencor is the large dot.

Xencor competitors and peer comparison

Head to head with its named competitors (XNCR vs AMGN vs GMAB.CO vs ZYME)
CompanyMarket cap6M returnRevenue growthOp. marginEV / SalesReq g
Xencor XNCR$2.58B+204%+34%-73%11.7×n/a
Amgen AMGN$240B+34%+9%36%7.2×1.6%
Genmab A/S GMAB.CO$30.8B+103%+15%31%8.4×11.6%
Zymeworks ZYME$1.81B+5%+98%17%8.9×n/a
Janux Therapeutics JANX$631M-28%+133%-599%n/an/a
Immunocore Holdings Plc Shs Sponsored American Depositary Shares Repr 1 Sh IMCR$1.44B-7%+13%-7%2.3×n/a

How Xencor compares with its peers

Peer set: Industry: the same industry and sector in any market, nearest in size. This is the same default set the interactive Competitor Analysis opens with.

Xencor against its 20 peers (data as of 18 Nov 2026)
MeasureXNCRPeer medianRank in peer set
1-month return+37.9%-4.0%highest of 21
6-month return+203.8%-4.6%highest of 21
Distance from 52-week high-15.3%-32.5%5th highest of 21
Revenue growth (TTM)+33.5%+9.4%4th highest of 17
Operating margin-72.7%-2.6%6th lowest of 18
EV / Sales11.7×7.7×7th most expensive of 17
ROIC minus cost of capital-45.3 pp-6.5 pp3rd lowest of 16

Peer table

Peer set: Industry: the same industry and sector in any market, nearest in size
CompanyMarketMarket cap6M returnRevenue growthOp. marginEV / SalesReq gDelivered g
Xencor XNCRUnited States$2.58B+204%+34%-73%11.7×n/an/a
Xiamen Amoytop Biotech 688278.SSChina$2.56B-27%+18%27%4.3×-0.6%+36.0%
MBX Biosciences MBXUnited States$2.65B+70%n/an/an/an/an/a
Walvax Biotechnology 300142.SZChina$2.48B-26%-23%5%9.4×29.5%-3.8%
HLB 028300.KSSouth Korea$2.69B-49%+26%-96%38.7×n/an/a
Sunshine Lake Pharma 6887.HKHong Kong$2.72B-7%+20%-3%5.9×n/an/a
Zai Lab 9688.HKHong Kong$2.79B+23%0%-63%5.4×n/an/a
Bavarian Nordic A/S BAVA.CODenmark$2.82B+23%-8%18%2.6×-4.3%+27.4%
Hebei Changshan Biochemical Pharmaceutical 300255.SZChina$2.33B-59%0%-25%19.4×n/an/a
XtalPi 2228.HKHong Kong$2.87B-34%+4%-127%21.3×n/an/a
Arcus Biosciences RCUSUnited States$2.27B-34%-58%-475%17.6×n/an/a
Rubicon Research RUBICON.NSIndia$2.94B+68%+37%21%13.2×n/an/a
Lakefront Biotherapeutics LKFT.ASNetherlands$2.26B+31%+223%64%n/an/an/a
Denali Therapeutics DNLIUnited States$2.95B-2%n/a-2,488%115.4×n/an/a
Vimian VIMIAN.STSweden$2.26B+51%+8%19%5.0×13.4%+44.5%
SKBS 302440.KSSouth Korea$2.25B-12%+11%-23%4.3×n/an/a
Dyne Therapeutics DYNUnited States$2.97B-10%n/an/an/an/an/a
Telix Pharmaceuticals TLX.AXAustralia$2.99B-2%+27%-1%3.8×n/an/a
Pharvaris PHVSUnited States$2.21B+7%n/an/an/an/an/a
ADMA Biologics ADMAUnited States$3.01B+58%+6%45%6.0×-0.8%+64.6%
Beam Therapeutics BEAMUnited States$2.17B-22%+163%-268%9.4×n/an/a

Questions

Who are Xencor's main competitors?
Named competitors: Amgen (bispecifics) (AMGN), Genmab (GMAB.CO), Zymeworks (ZYME), Janux Therapeutics (JANX), MacroGenics (private or unlisted), Immunocore (IMCR). The cockpit's measured peer set (industry) also includes Xiamen Amoytop Biotech (688278.SS), MBX Biosciences (MBX), Walvax Biotechnology (300142.SZ), HLB (028300.KS), Sunshine Lake Pharma (6887.HK), Zai Lab (9688.HK).
Is Xencor expensive compared with its peers?
On ev / sales it trades at 11.7× against a peer median of 7.7×, 7th most expensive of 17 in its peer set.
How has Xencor stock performed?
Over six months to 18 Nov 2026 the shares returned +203.8% against -4.6% for the median peer; over one year +120.2%.

How these numbers are made. Returns are close-to-close in local currency. Revenue growth and margins are trailing twelve months. Req g is the revenue growth that today's enterprise value requires for seven years at the company's own cost of capital; Delivered g is what it actually grew; the gap is the hurdle (honest precision about ±8 points, so read the ranking more than the decimal). No fair values, price targets or analyst ratings are shown, by design. Method and validation.